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The photodynamic response of two rodent tumour
models to four zinc (11)-substituted phthalocyanines
JE Cruse-Sawyer' 2, J Griffiths3, B Dixon1 and SB Brown2
'Research School of Medicine, Departments of 2Biochemistry and Molecular Biology and 3Colour Chemistry; Centre for Photobiology and Photodynamic
Therapy, The University of Leeds, Leeds, UK
Summary Four novel zinc (I1)-substituted phthalocyanines, varying in charge and hydrophobicity, were evaluated in vivo as new
photosensitizers for photodynamic therapy. Two rat tumours with differing vascularity were used: a mammary carcinoma (LMC,) and a
fibrosarcoma (LSBD1), with vascular components six times higher in the latter (10.8% ± 1.5) than in the former (1.8% ± 1.4). Each sensitizer
was assessed for tumour response relative to normal tissue damage, and optimum doses were selected for further study, ranging from 0.5 to
20 mg kg-'. Interstitial illumination ofthe tumours was carried out using a 200-gm-core optical fibre with a 0.5 cm length ofdiffusing tip, ateither
680 or 692 nm, depending on the sensitizer. Light doses of between 200 and 600 J were delivered at a rate of 100 mW from the 0.5-cm
diffusing section of the fibre. Maximum mean growth delays ranged from 9 to 13.5 days depending on sensitizer and type of tumour, with the
most potent photosensitizer appearing to be the cationic compound. Histopathological changes were investigated aftertreatment to determine
the mechanism by which tumour necrosis was effected. The tumours had the appearance of an infarct and, under the conditions used, the
observed damage was shown to be mainly due to ischaemic processes, although some direct tumour cell damage could not be ruled out.
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Photodynamic therapy (PDT) is a method ofcancer treatment that
has been clinically applied to the eradication or palliation of
tumours at various sites, including bladder (Benson, 1985), brain
(Kaye et al, 1987), lung (Okunaka et al, 1991), chest wall
(Sperduto et al, 1991), skin (Caimduffetal, 1994) and oesophagus
(Moghissi et al, 1995). The only photosensitizer so far approved
for general use is Photofrin, which is a complex mixture of
porphyrin monomers and oligomers. However, this drug also has
relatively low light absorption in the red region of the spectrum,
where light penetration in tissue is greatest, and also induces a
prolonged skin photosensitivity (Richter et al, 1991).
To overcome the problems associated with the limited depth of
lightpenetration, chemical purity and stability, low absorption coeffi-
cient and skin photosensitivity, possible alternatives to the haemato-
porphyrin photosensitizers have been investigated. One such group is
the phthalocyanines, which are synthetic porphyrin analogues. A
number of phthalocyanine compounds have been tested in vitro
(Chan et al, 1991; Boyle et al, 1993) and in vivo (Barr et al, 1991;
Boyle et al, 1992) and show sufficient potential for clinical use to
merit further investigation. They demonstrate strong absorbance in
the red region of the spectrum and the potential for a greater PDT
effect is enhanced by the increased tissue penetration by light of
longer wavelength. They also appear to induce a smaller degree of
skin photosensitivity than haematoporhyrin derivative (HPD) under
experimental conditions (Roberts et al, 1989) and the compounds
studied appear to be rapidly cleared from the skin.
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For our studies, we have developed a series of zinc phthalo-
cyanines. Zinc, a diamagnetic metal, extends the lifetime of the
metastable triplet state (Rosenthal, 1991) and therefore enhances
phototoxicity. It is also acknowledged that the polarity of the
phthalocyanine affects tumour retention and cell membrane pene-
tration (van Lier and Spikes, 1989). In the current work, we have
used four novel zinc phthalocyanines differing in charge and
hydrophobicity.
Many experimental tumours of different histologies and origins
have been used when investigating the efficacy and mode ofaction
of new photosensitizers. Each has structural differences, including
the organization of their vascular morphology, depending on the
tissue oforigin andthe site oftransplantation. For these studies, two
tumour models of differing vascularity were chosen to investigate
the photodynamic effect ofthe four photosensitizers in vivo, and to
identify any structure-related distinctions in tumourresponse.
We have therefore investigated the effect of photodynamic
therapy in two transplantable rat tumour models, with four substi-
tuted zinc (II) phthalocyanines that are water soluble and demon-
strate a range of ionic charges (anionic, neutral and cationic),
togetherwith strong light absorbance in the 660-700 nm range and
good photosensitizing properties in vitro (unpublished).
MATERIALS AND METHODS
Tumour models
Each spontaneous tumour was transplanted and used in their strain
of origin. The first was a poorly differentiated fibrosarcoma
(LSBD,) implanted subcutaneously, as a 2 mm fragment, in the
right flank offemale BDIX rats weighing between 180 and 250 kg
(Gilson, 1990). The second was a poorly differentiated mammary
carcinoma (LMCI) implanted as a 2-mm pellet of minced tumour
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Table 1 Spectroscopic data for the zinc-polysubstituted phthalocyanines
Sensitizer xmax 6max Xmax e,f,, k
(nm) (I mol-' cm-') (nm) (I mol-' cm-') (n-octanoV
(DMFb) (DMFb) (MEMa) (MEM') water)
ZnTCPc 680 5.3 x 104 636 2.35 x 104 5 x 10-2
ZnTSAPc 673 1.46 x 105 626 4.28 x 104 2 x 10-3
ZnPPc 670 1.12 x 105 629 3.90 x 104 5 x 10-2
ZnTSPc 672 1.42 x 105 632 2.22 x 104 2 x 10 4
672 2.22 x 104
aMinimal essential medium (MEM) containing 10% calf serum at pH 7.4;
bDimethyl formanide
butanol; zinc phthalocyanine tetra-[NN-bis (hydroxyethyl)
sulphonamide] (ZnTSAPc), this is a neutral compound with Xex
and Xem (in butanol) at 610 and 684 nm respectively; zinc phthalo-
cyanine dicarboxylic acid dicarboxyamide (disodium salt)
(ZnTCPc), this is an anionic compound with Xex and Xem (in
butanol) at 620 and 692 nm respectively; bis-methylene-
pyridinium zinc phthalocyanine (ZnPPc), this is a cationic
compound with ex and item (in butanol) at 605 and 682 nm
respectively.
All sensitizers were dissolved in saline or phosphate-buffered
saline (PBS) and then filter sterilized using a 0.22-jim filter
(Gelman Sciences, Northampton, UK) before injection.
x x
N
N Zn
) X-' < X -...\
ZnTCPc X = COO-Na+
ZnTSAPc X = SO2N(CH2CH2OH)2
ZnPPc X= - NCH2-
ZnTSPc X = SO3-Na+
Figure 1 Structure of the substituted zinc phthalocyanines, where X is the
substituent group
tissue in the right flank ofmale Johns' Strain Wistar rats weighing
between 250 and 350 g (Moore, 1976). All animals were weighed
and their tumours measured daily once palpable. The mean tumour
diameter was calculated from measurements of three orthogonal
axes using Vernier callipers.
All animals were inbred virgins and were housed under subdued
lighting operated under a 12 h dark/12 h light regimen. The
animals were supplied with food and water ad libitum, and experi-
ments were carried out within the UKCCCR Guidelines for the
Welfare ofAnimals in Experimental Neoplasia (1988).
Photosensitizers
The zinc phthalocyanines were synthesized in the Department of
Colour Chemistry, University of Leeds, UK. Preparative details
and characterization data have been reported elsewhere (Griffiths
et al, 1997), and the visible absorption spectroscopic data are
briefly summarized in Table 1. The tetrasulphonate dye has a very
low distribution coefficient, of about 10-4, and the other dyes are
slightly less hydrophilic with values an order of magnitude lower.
The sulphonamide is somewhat more hydrophilic than the
carboxylic acid and the pyridinium dyes, the latter two being
similar in their distribution coefficients (Table 1). Each phthalo-
cyanine was produced as an isomeric mixture with the substituent
groups present in the 3 or 4 position in the molecule (Figure 1).
The four compounds used were: zinc phthalocyanine tetrasul-
phonic acid tetra-sodium salt (ZnTSPc), this is an anionic
compound with an excitation maximum (kex) and fluorescence
emission maximum (Xem) at 608 and 686nm, respectively, in
Photodynamic therapy of tumours
Animals were allocated for randomized treatment (n = 6 for each
treatment and control group) when their tumours first reached a
mean diameter of 8-10 mm (T-day). Tumours differing by 2 mm or
more in any ofthe three measured orthogonal planes on T-day were
excluded from the study. Photosensitizers were injected, at the
appropriate dose (ZnTCPc and ZnTSAPc, 20 mg kg-'; ZnPPc,
0.5 mg kg-'; ZnTSPc, 10 or 5 mg kg-', depending on strain of
animal), via a lateral caudal vein for females or the penile vein for
males. These drug doses were determined in pilot studies (Table 2),
in which maximum growth delay was assessed together with
morbidity of the underlying muscle and gut (Cruse-Sawyer, 1996).
Time delays between injection and treatment of2, 24 and 48 h were
investigated but there was no significant improvement over a time
interval of 2 h, either in terms ofgrowth delay or morbidity, at 24 h
or 48 h intervals. After 2h, a general anaesthetic was administered
as an intraperitoneal injection, consisting ofa6:1 mixture ofKetalar
100 mg ml-' (Parke Davis, Gwent, UK) to Rompun 2% solution
(BayerUK, Suffolk, UK) at a dose of0.01 ml g-'. This regimen was
chosen to minimize stasis ofthe ileum during treatment.
The skin overlying the tumour and surrounding area was closely
shaved and the animal maintained at normal body temperature.
The tumour was then swabbed using Hibiscrub and a 19G x 11/2
needle inserted through the skin and central axis of the tumour. A
200-,um-core optical fibre with a 0.5-cm cylindrical diffusing tip
(Feather et al, 1989) was inserted and the needle removed.
Interstitial illumination of the tumours was then carried out using
narrow bandwidth light generated by a copper vapour laser-
pumped dye laser (Oxford Lasers, Abingdon, UK). The wave-
lengths used in this study were 692 nm (ZnTCPc andZnTSPc) and
680 nm (ZnTSAPc and ZnPPc). The tumours received light doses
calculated to be 200-600 J, delivered at a rate of 100 mW from the
0.5-cm diffusing section of the fibre. The temperature between
tumour and underlying muscle was monitored during treatment in
a number ofanimals for each light dose, using a thermocouple.
Three control sets of animals were included in each treatment
group: (1) injection of0.5 ml saline only; (2) sensitizer at the treat-
ment dose but with no illumination; (3) tumour illumination with
light alone at 600 J.
After control and PDT treatments, the animals were weighed and
the tumour measured 5-6 days per week. Providing the weight of
the animal did not decrease by more than 20% below its weight
before treatment, the tumour was allowed to grow until it reached a
mean diameter of 20 mm. At post mortem, the tumour was excised
intact, leaving a small section ofskin attached to indicate its orienta-
tion, andprepared forhistological examination. Any signs ofnormal
tissue response were recorded and samples taken forhistology.
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Table 2 Results of pilot studies showing tumour growth delay (in days) after PDT of LSBD1 and LMC, tumours with the zinc-polysubstituted phthalocyanines
(n = 2-3)
Sensitizer Time Drug dose Light dose (J cm-2)
(h) (mg kg-')
200 300 400 500 600
LSBD,
ZnTCPc 2 5 0 0 0 0 0
10 0 0 4.5 ± 0.7 4.8 ± 0.4 2.5 ± 3.5
20 2.8±1.1 2.5±0.7 5.3±0.4 10.5±0.7 10.8±0.4
ZnTSAPc 2 5 0 1.5 ± 0.7 1.8 ± 0.4 4.0 ± 1.4 3.3± 1.1
10 0.5 ± 0.7 3.0 ± 1.4 3.0± 2.8 4.3± 2.5 4.5 ± 0.7
20 7.0±0.7 5.3±0.4 6a 8.8+ 1.8 10.5+2.1
ZnTSPc 2 5 7.8 ± 1.0 7.5 ± 0.7 9.3 ± 1.0 1O.a 11.5a
10 3.5±2.0 4.0±2.0 9.3±0.4 a a
20 7.0 ± 0.7 a a a a
ZnPPcb 2 0.1 0 1.0±1.4 1.5±2.1 3.0±2.8 2.0±0
0.5 1.3 ± 0.4 4.0 ± 1.4 6.5± 2.1 7.8± 1.1 9.5± 0.7
1 9a a 10.0±2.8 a a
2 7.5 ± 0.7 a 8a 1o.0a a
3 6.5±2.1 a 8a 9a a
LMC
ZnTCPc 2 5 0 0 0 0 0
10 0.8+1.1 1.3±1.8 2.5±0 2.8±0.4 2.3+1.1
20 0 2.3±1.1 5.8±1.1 6.3±0.4 6.5±0
ZnTSAPc 2 5 5 ± 0 3.8± 1.1 7.5a 8.8 ± 4.5 8a
10 3+1.4 10.5±6.4 5.0±2.8 11 ±0 8.5±0.7
20 3.3± 1.1 4.3±0.4 5.3± 1.8 6a 7.8± 1.1
ZnTSPc 2 5 2.0 + 0 2.8 ± 0.4 4.5 ± 0.7 4.0 ± 2.8 7.5 ± 0.7
10 2.8 ± 0.4 6.8± 1.1 4.8 ± 1.8 7.8± 1.1 10.0 ± 1.4
20 4.0±1.4 4.5±2.1 4.5±0.7 8.3±1.1 8.5±0.7
aAnimal(s) developed normal tissue damage before completion of experiment. bZnPPc demonstrated unacceptable PDT-induced morbidity even at 3 mg kg-',
so higher drug doses are not included.
Histological scoring of tumour vasculature
To determine the vascularity, six sections obtained from three 1 cm
diameter LSBDI and LMCI tumours were examined at a magnifi-
cation of x 400 with a Chalkley 25-point eyepiece graticule
(Graticules, UK). Starting at the capsule of the tumour underlying
the skin, adjacent fields were scored across the whole of the
tumour section to the capsule overlying the abdominal wall. After
scoring, the section was rotated 900 and the procedure repeated.
The score for each field was recorded for the number of times
the points coincided with vascular components (V - including
blood cells, endothelial cells, vessel lumen and vessel wall),
tumour cells (T), stroma (S) and tissue spaces (TS). Sufficient
fields were scored to give a total of approximately 6000 observa-
tions for each type of tumour. The percentage of the section
occupied by vascular components was calculated by:-
V
% Vasculature = x 100
V+ T+ S + TS
Analysis of tumour response to photodynamic therapy
Tumour growth curves were calculated for each group of similar
treated animals and were plotted against time. Tumour growth
delay was calculated from:-T, - TO = TD, where T1 is the mean time
(days) for treated tumours to grow from 10 to 15 mm, To is the
mean time (days) for untreated tumours to grow from 10 to 15 mm
and TD is the tumour growth delay in days.
Tumour growth delay was used to assess PDT dose response and
to compare the effectiveness of the different photosensitizers used.
A Student's t-test was used, applying the Bessel correction when
samples were small (n < 10), to assess the significance ofthe data.
RESULTS
Growth response of tumours
In all control groups, light or sensitizer alone caused no deviation
of the normal growth rate of either of the tumours investigated.
There was no apparent dark toxicity with these compounds at
20 mg kg-'. We have also demonstrated that the rate at which the
light was delivered, i.e. 100 mW using the 0.5-cm diffusing tip
fibre, produces no hyperthermic effects (C Lowdell and B Dixon,
personal communication). In the several animals in which the
temperature between the tumour and the underlying muscle had
been monitored, the maximum temperature measured was 41°C.
Any alteration in the growth rate of the tumour, therefore, is
considered to be a true PDT response.
The pattern ofPDT response with ZnTCPc, ZnTSPc and ZnPPc
was similar for both the tumour models. After an initial oedema-
tous response, resulting in an increase in measured tumour diam-
eter, there was a subsequentregression to a size less than that at the
time of illumination, with the tumour remaining at approximately
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Figure 2 Growth response of the LSBD, tumour to interstitial PDT 2 h after
injection of 0.5 mg kg-' ZnPPc and illuminated with 200 J (-), 300 J (V),
400 J (V), 500 J (E) and 600 J (U) of 680-nm light. The control growth curve
is shown by open circles (0)
7 mm mean diameter for between 5 and 7 days. After this period,
tumour regrowth was detected, except with ZnPPc at 600 J, when
regression of the LSBD, tumour continued until a mean tumour
diameter of 5 mm was reached (Figure 2). There was no evidence
of regrowth in two out of the three tumours treated at this light
dose. With ZnTSAPc, however, the measured tumour diameter
decreased only to that of the original implant at the time of treat-
ment (8-10 mm) with no further tumour regression.
Significant growth delays were achievable in both tumours after
PDT with all four phthalocyanines (Figure 3). The LSBD1 tumour,
however, was more responsive to PDT at lower light doses than the
LMCI.
Tumour morphology at post mortem
Central necrosis with both untreated LSBDI and LMC1 tumours
was usually irregular in distribution, with no clear boundaries
between necrotic and viable tumour. As the diameter of the
untreated tumours reached approximately 15 mm, the central core
of coagulative necrosis increased in size. The development of
necrosis in control tumours followed this same pattern.
After PDT, a marked difference in the necrotic component ofthe
tumour was seen with all the photosensitizers under investigation.
Both tumour models developed a necrotic centre with clearly
defined borders. The mean diameter ofthis central area was always
between 6 and 10 mm, irrespective ofthe size ofthe overall tumour
removed at post mortem. When the treated tumours were allowed
to regrow to 20 mm or more, this necrotic core was also
surrounded by a pattern of necrosis of the type and character seen
in untreated tumours. However, the boundary between 'normal'
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Figure 3 Comparison of tumour growth delays, at 15-mm diameter,
after PDT
and PDT-induced necrosis remained clearly defined. Treated
tumours had centres that were of a very firm, solid consistency. The
colour of the induced necrosis also differed to that normally seen,
and was most marked with theLSBDI tumour. Untreated, its centre
was haemorrhagic and typically red/brown in colour, but after PDT
the necrotic centre was a pale yellow (Figure 4).
Tumour histology
For control tumours greater than 15 mm in diameter, cords of
viable malignant cells surrounding the capillaries (Figure SA)
were located throughout zones of necrosis composed ofcells with
pyknotic or karyorrhectic nuclei. Within 12 h of treatment, there
was massive haemorrhage throughout the whole of the tumour
with extravasation of erythrocytes (RBC) into the surrounding
parenchyma (Figure SB). By 48 h, however, both the macroscopic
appearance and the histology of the treated tumours were notice-
ably different. The necrotic centre had become clearly defined and
had changed in colour and texture. The material within the capsule
now consisted of cells with pyknotic nuclei amidst extravasated
RBC (Figure SC).
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Figure 4 (A) Control LSBD, at 1 cm diameter demonstrating 'normal'
necrosis. (B) PDT-treated LSBD, tumour, with an area of 'normal'
haemorrhagic necrosis surrounding a 7-mm core of PDT-induced necrosis
By 5-9 days there were viable tumour cells around the external
margin of the encapsulated necrosis, with a dense band consisting
of inflammatory infiltrate, pyknotic cells and cell debris under-
lying the capsule (Figure 5D). The central core of necrosis
contained both pyknotic and karyorrhexic cells but with no histo-
logical evidence of viable tumour cells. The subcapsular band was
gradually replaced by a band of karyhorrexic cells by day 12. All
tumours sampled between days 12 and 15 after illumination
demonstrated the same banded appearance around the perimeter of
the necrotic centre (Figure SE). Viable tumour cells were present
on one side ofthe capsule while on the inneredge there was aband
of karyhorrexic cells, followed by a band of pyknotic cells and
debris of 20 gm mean width that surrounded a central core of
pyknotic and karyhorrexic cells, interspersed with collagen fibres
and large spaces.
There was a highly significant difference (P < 0.01) in the mean
vascularity of the two untreated tumour models, with vascular
components six times higher in the LSBDI tumour (10.8% ± 1.5)
than in the LMCI tumour (1.8% ± 1.4).
The central core of encapsulated necrosis was examined at
higher magnifications to investigate blood vessels. Nearly all the
tumour capillaries were congested with RBC and cell debris, or
contained thrombi. There were also many sinusoids containing
fibrous material that were not in evidence in the necrotic areas of
untreated tumours.
DISCUSSION
Previous work on phthalocyanines has suggested that the more
hydrophobic the derivative, the greater the uptake and photo-
activity (Paquette et al, 1991). However, our hydrophilic zinc-
substituted phthalocyanines demonstrated good photosensitizing
properties in vivo (Table 3) and show promise as alternative photo-
sensitizers to Photofrin.
After PDT, there was oedema of the tumour and surrounding
tissues, which increased tumour diameter, although skin reactivity
was appreciably less than in our previous sensitizer studies. This
oedema was short lived, 24-48 h, after which the tumour volumes
decreased. With ZnTCPc, ZnTSPc and ZnPPc, this continued until
the tumours were smaller than at treatment. This suggests that
tumour cell death occurred directly as a result of PDT, with these
three sensitizers. However, there was a diminished PDT effect
observed with the less vascular tumour (LMC,), demonstrated by
shorter growth delays (Table 3). Although there is a reduction in
oxygen availability in this tumour, with 40% ofLMC, cells being
hypoxic, it could also imply that tumour response to PDT with
these three sensitizers may at least be due in part to vascular
damage. Only with ZnPPc at 600 J was there no obvious regrowth
of tumour.
With ZnTSAPc, however, after the initial wave of oedema, the
diameter of the tumour returned to that at treatment, with no
regression. The PDT target with ZnTSAPc may therefore be the
vasculature/stroma alone with no direct tumour cell kill. The
tumours remained at this size for at least 4 days. During this period
there was no evidence ofregrowth, indicating a period of stasis in
tumour cell production, with cells temporarily surviving under
hypoxic conditions preventing shrinkage of the tumour. This
would be consistent with the differing response seen with LMC1,
when a greater growth delay was observed at the higher light
doses. In comparison, forLSBDI, growth delay was constant, irre-
spective of light dose. The vessels supplying LMC1 are fewer and
more peripheral than those in LSBDI, and only at the higher light
doses may enough light, received by the tumour vasculature,
induce a significant photodynamic response.
It is difficult to compare the effects ofindividual sensitizers only
in terms of tumour growth delay. The concept of a 'photodynamic
threshold dose' has been suggested, defined as the total energy that
must be absorbed by the photosensitizer per unit volume of tissue
to produce necrosis (Wilson et al, 1986). This would indicate the
inherent efficiency of a particular sensitizer in a specific tissue. In
this study, with ZnPPc, the lack of response in terms of tumour
growth delay at 200 J may be accounted for by not achieving the
threshold dose. Uptake of ZnPPc by the tumour (after injection at
10 mg kg-') has been demonstrated to be lower than that of
ZnTCPc and ZnTSPc (Timmins, 1990). If this is considered for
the far lower injected dose (0.5 mg kg-' compared with 20 and
5 mg kg-' for ZnTCPc and ZnTSPc respectively), then the
predicted tumour concentration ofZnPPc would be very low. This,
together with the two 'cures' obtained at 600 J, suggests that,
despite the relatively short growth delays observed (Table 3), this
cationic compound was the most potent of the four phthalocya-
nines studied. The distribution of a sensitizer throughout a tumour
may also be inhomogeneous and, depending on localization, could
differ between sensitizers, resulting in differing responses to PDT.
Similarly, the subcellular distribution of the different sensitizers
could well be important when determining their efficacy. Any
evidence for there being different mechanisms, or sites, of PDT
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Figure 5 (A) Untreated LMC, at 15-mm diameter, with cords of tumour cells (T) surrounding capillaries (C) dispersed throughout zones of necrosis (N) (x 100).
(B) Extravasation of erythrocytes (E) in LSBD1 at 12 h after PDT (x 150). (C) LSBD, 48 h after PDT demonstrating extensive pyknosis throughout the
encapsulated tumour (x 150). (D) By 9 days viable cells (V) are observed around the encapsulated necrosis (N), with a band of inflammatory infiltrate underlying
the capsule (I) (x 150). (E) A clearly demarcated border can be seen between PDT-induced necrosis (N) and viable malignant cells (V) by 15 days after
illumination (x 100)
action is in the differences observed in tumour response, after
PDT, between ZnTSAPc and the other three compounds. With
ZnTSAPC, tumours returned to, and then remained at, pretreat-
ment size, whereas with the other compounds, there was a marked
tumour regression.
The in vivo efficacy ofthe tetrasulphonated compound, ZnTSPc,
is interesting given that the tri- and tetra-sulphonated compounds
had previously been demonstrated to be less effective, both in vivo
(Brasseur et al, 1988) and in vitro (Berg et al, 1989), than the lesser
substituted compounds. However, we have previously shown that a
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Table 3 Mean tumour growth delay (± s.e.m.) at 15 mm after PDT of LMC,
and LSBD1 using the substituted zinc phthalocyanines. (n = 4-6)
Sensitizer Mean tumour growth delay (days)
200J 300 J 400J 500 J 600 J
LMC1
ZnTCPc 6.0 ± 1.4 7.0 ± 1.0 8.4 ± 1.9 9.6 ± 2.2 9.1 ± 1.4
ZnTSAPc 4.3 ± 1.7 4.3 ± 0.9 6.1 ± 1.3 7.2 ± 1.7 12.2 ±0
ZnTSPc 8.1 ± 1.4 9.2 ± 1.0 12.4 ± 1.5 11.8 ±3.0 13.6 ± 1.9
LSBD,
ZnTCPc 9.1 ±1.7 8.1 +3.6 11.9±2.2 13.3±3.6 11.9±3.6
ZnTSAPc 8.5 ± 1.7 8.7 ± 2.3 8.8 ± 2.1 8.8 ± 0.7 9.3 ± 2.3
ZnPPc 0.5 ± 1.2 3.5 ± 1.5 7.9 ± 3.1 6.5 ± 2.6 -
ZnTSPc 10.7 ± 1.8 12.7 ±2.8 13 ± 1.5 13.1 ±2.0
wavelength shift of only 12 nm has a marked effect on the tumour
response after PDT with ZnTSPc (Griffiths et al, 1994), and such a
wavelength effect may account forthe strong PDT response that we
have observed with these substituted compounds.
The concept of a photodynamic threshold dose has also been
linked with the presence or absence ofa distinctive zone oftumour
necrosis (Bown et al, 1986). However, in contrast to the studies of
Bown and others (van Hillegersberg et al, 1992), no evidence of
increasing necrosis with increasing light dose was obtained in this
study. Neither was there any similarity in the necrosis seen after
light alone compared with that seen after PDT. We measured the
mean diameter of PDT-induced necrosis from 7 days after PDT
onwards, in sagittal sections, and this was between 7 and 10 mm,
with no correlation between the diameters and higher light doses.
In treatment groups in which there was little or no PDT-induced
growth delay, there were also fewer tumours showing evidence of
PDT necrosis. This suggests an 'all or nothing' tumour response,
which is similar to that seen in other tissues (Dereski et al, 1989).
The necrotic centres observed in our tumours had the gross
appearance of an infarct. Up to 24 h, the necrotic centre contained
large quantities of red cells leaking through damaged ischaemic
microcirculation. Within 48 h, the infarct had a very clearly
defined border, with the centre becoming paler and firmer as a
result of the possible swelling of dead cells and the subsequent
squeezing offluid out ofthe interstitial tissue in the infarcted area.
Tumours left in situ for more than 5 days had developed the classic
dull yellow of an infarct in solid tissue (Woolf, 1986). The pres-
ence of an infarct suggests that blood vessels are the primary site
ofaction for PDT with these phthalocyanines.
The extravasation of RBC into the perivascular stroma at 24 h
was consistent with that seen using other photosensitizers (Nelson
et al, 1988). This haemorrhagia was evidence ofincreased vascular
damage. Whether this increased permeability ofthe vessels is as a
result of the direct destruction of the endothelial cells or of the
damage to the underlying subendothelial matrix is uncertain.
Others have reported complete destruction of the microvascular
endothelial cells lining the capillaries at 24 h (Klaunig et al, 1985),
with severe cell damage being evident at 1 h (Winther and Ehlers,
1988). Endothelial cell damage, however, has been suggested as
occurring as a secondary response after complete disruption ofthe
subendothelial zone, with the ultrastructure of the endothelial cell
appearing normal, even though there was severe damage to the
subendothelial zone (Nelson et al, 1988) and subsequent extrava-
sation oferythrocytes.
If stromal blood flow is reduced or ceases altogether, malignant
cells within the tumour may only survive for =24 h (Denekamp,
1992). Vessels and sinusoids in theLSBDI tumourwere shown to be
at least partly occluded, either by RBC, thrombi or other fibrinous
material. After PDT, erythrocytes are known to swell (Ben-Hur and
Orenstein, 1991). This, and the release ofthe vasoactive substances
prostaglandin and thromboxane, which cause vasoconstriction and
platelet aggregation (Fingar et al, 1992), may result in congestion of
the capillaries. Similarly, blockage ofthe capillaries can be effected
by thrombi formation due to the release of various clotting factors
from the damaged endothelial cells (Ben-Hur et al, 1988) or to the
production of tumour necrosis factor by PDT-treated macrophages
(Chaplin, 1991). The fibrinous material that we observed only in the
sinusoids oftreated tumours may be a result ofthe photohaemolysis
of RBCs, whereby the cells eventually lyse leaving a fibrin clot and
cell debris. As the formation ofathrombus involves the 'trapping' of
RBCs in a fibrin net, they are exposed to light for considerably
longerthan when in free circulation, thus receiving an effective PDT
dose (Ben-Hur and Orenstein, 1991). The resultant blockage of
vessels by any of the above mechanisms could account for the
appearance, after48 h, oftumour cells containing pyknotic nuclei.
The appearance of the dense subcapsular band between 5 and
9 days was probably as a result of the accumulation of debris
from the breakdown of cells or fragmentation of their nucleus,
producing karyhorrexic cells in the necrotic centre. The displace-
ment ofthis band by a layer ofkaryhorrexic cells would be consis-
tent with the change over time from cells undergoing pyknosis
followed by karyhorrexis.
It is not clear whether development of a subcapsular band of
collagen fibres around the volume of necrosis was derived from the
original capsule or in response to infarction. If the former, then the
whole ofthe treated tumourhad undergone necrosis, and subsequent
regrowth was initiated by free cells in the surrounding normal tissue
at the time of treatment. Initially, these cells would not be vascular
dependent. This would be consistent with the nodular structure
around the periphery previously described. Ifthis collagen band was
due to an infarct, then the larger peripheral vessels may have been
primarily damaged by PDT and not those within the tumour. This
would then explain why the gross appearance and histopathology of
the necrotic area were the same for both tumour models, even
though the vascularity ofthe two tumours was different.
From the data obtained in this study, these four novel substituted
zinc phthalocyanines would appear to be efficient photosensitizers
in vivo, although perhaps differing in their mode of action. While
ranking is inappropriate in terms of growth delay, the most potent
of these sensitizers would appear to be the cationic compound
ZnPPc. The two types of tumour investigated demonstrate
differing quantitative responses to PDT, and this is consistent with
the findings of other workers (Chan et al, 1988). The vasculature
of a tumour is characteristic of a particular type of neoplasm
(Lewis, 1927), and the response ofthese tumours can be correlated
with their vascularity, with the more vascular (LSBD,) demon-
strating a greater response. The appearance of these tumours, both
macroscopically and microscopically, indicates that the, damage
sustained is due primarily to vascular injury, although there is
some indication that direct tumour cell kill may also occur.
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